Home Cart Sign in  
Chemical Structure| 1060816-67-2 Chemical Structure| 1060816-67-2

Structure of 1060816-67-2

Chemical Structure| 1060816-67-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1060816-67-2 ]

CAS No. :1060816-67-2
Formula : C7H6ClN3
M.W : 167.60
SMILES Code : CN1C=CC2=CN=C(Cl)N=C21
MDL No. :MFCD13189420
InChI Key :WOIRQILACBXPIQ-UHFFFAOYSA-N
Pubchem ID :57415888

Safety of [ 1060816-67-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 1060816-67-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 9
Fraction Csp3 0.14
Num. rotatable bonds 0
Num. H-bond acceptors 2.0
Num. H-bond donors 0.0
Molar Refractivity 43.8
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

30.71 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.09
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.58
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.62
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.11
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.58
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.6

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.48
Solubility 0.555 mg/ml ; 0.00331 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.84
Solubility 2.45 mg/ml ; 0.0146 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.71
Solubility 0.328 mg/ml ; 0.00195 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.2 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.44

Application In Synthesis of [ 1060816-67-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1060816-67-2 ]

[ 1060816-67-2 ] Synthesis Path-Downstream   1~7

  • 1
  • [ 335654-06-3 ]
  • [ 74-88-4 ]
  • [ 1060816-67-2 ]
YieldReaction ConditionsOperation in experiment
77% Step-1: 2-Chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine [0182] To a stirred solution of 2-chloro-7H-pyrrolo[2,3-d]pyrimidine (1 g, 6.5 mmol) in MeCN (25 mL) at 5 oC was added NaH (313 mg, 7.8 mmol). The resultant mixture was brought to room temperature and stirred for 30 min. Then MeI was added at 0 oC and continued stirring at room temperature for overnight. The reaction mixture was filtered through a pad of celite and washed with MeCN (10 mL). The filtrate was concentrated and recrystallized from Et2O. The mother liquor was concentrated and purified by ISCO (SiO2: DCM/EtOAc 0 to 30%). Altogether, the recrystallized and purified provided the pure compound (835 mg, 77%).
47% With potassium carbonate; In N,N-dimethyl-formamide; at 20℃; for 3h;Sealed tube; Step 1. 2-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidineTo a solution of 2-chloro-7H-pyrrolo[2,3-d]pyrimidine (27 mg, 0.16 mmol, prepared as reported in Bioorganic and Medicinal Chemistry Letters, 16(22), 5778-5783 (2006)) in DMF (0.15 mL) was added potassium carbonate (67 mg, 0.48 mmol), followed by methyl iodide (10 microL, 0.16 mmol). The mixture was stirred in a sealed vial at RT for 3 h. The reaction was diluted with DCM and acetonitrile, filtered and concentrated. The product was purified by flash column chromatography on silica gel, eluting with 0-50% ethyl acetate in hexanes to afford product as a white solid (13 mg, 47%). LCMS (M+H)+: 167.9, 169.9.
47.4% To a solution of NaH (106.6 mg, 2.67 mmol) in THF (5 mL) was added 2-chloro- 7H-pyrrolo[2,3-d]pyrimidine (500 mg, 2.54 mmol) at 0C and stirred for 30 minutes at the same temperature. CH3I (1.5 g, 10.2 mmol) was added at 0C and the combined mixture stirred for 3 h at 15C. After TLC showed the reaction was complete, the mixture was diluted with water 20 mL) and extracted with ethyl acetate EA (2x20 mL) and the combined organic layers were washed with brine (30 mL), dried over Na2S04 and concentrated to give the title compound (254 mg, 47.4%) as colorless oil which was used in next step without further purification.
  • 2
  • [ 941687-74-7 ]
  • [ 1060816-67-2 ]
  • [ 1257067-90-5 ]
YieldReaction ConditionsOperation in experiment
Step 2. 3-[1-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)pyrrolidin-3-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile3-Pyrrolidin-3-yl-3-[4-(7-[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile (26 mg, 0.060 mmol; from Example 15, Step 3) and <strong>[1060816-67-2]2-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine</strong> (12.0 mg, 0.0716 mmol) were dissolved in NMP (0.050 mL) and N,N-diisopropylethylamine (42 microL, 0.24 mmol) was added. The mixture was heated to 135 C. for 60 min in the microwave. After removal of solvent, the residue was stirred sequentially in 1:1 TFA/DCM for 1.5 h, concentrated, then in a solution in 1.0 mL methanol containing 0.2 mL EDA for 30 min. The product was purified via preparative-HPLC/MS (C18 column eluting with a gradient of ACN/H2O containing 0.15% NH4OH). 1H NMR (400 MHz, d6-DMSO): delta 12.13 (br s, 1H), 8.89 (s, 1H), 8.69 (s, 1H), 8.55 (s, 1H), 8.43 (s, 1H), 7.61 (d, 1H), 7.08 (d, 1H), 7.00 (d, 1H), 6.33 (d, 1H), 4.84 (dt, 1H), 3.91 (dd, 1H), 3.67 (dd, 1H), 3.62 (s, 3H), 3.46-3.27 (m, 4H), 2.96-2.84 (m, 1H), 1.77-1.59 (m, 2H); LCMS (M+H)+: 439.1.
  • 3
  • [ 64-18-6 ]
  • [ 1060816-67-2 ]
  • [ 1616099-35-4 ]
  • 1-(3,4-dihydroisoquinolin-2(1H)-yl)-3-((4-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)pyridin-2-yl)amino)propan-2-ol formate [ No CAS ]
YieldReaction ConditionsOperation in experiment
12% To a solution of <strong>[1060816-67-2]2-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine</strong> (100 mg, 0.6 mmol) in dioxane (4 ml) and H20 (1 mL) was added l-(3,4-dihydroisoquinolin-2(lH) -yl)-3- ((4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-yl)amino)propan-2-ol (292 mg, 0.716 mmol), Pd(dppf)Cl2 (44 mg, 0.06 mmol) and K2C03 (249 mg, 1.8 mmol) at 27C. The mixture was stirred for 16 h at 100C. After shown to be complete by TLC the reaction mixture was concentrated and the crude residue purified by prep-HPLC separation to give the desired title compound as a formate salt as a white solid (30.0 mg, 12%). 1H NMR (400 MHz, CHLOROFORM- J) ppm 3.21 (br. s., 2 H) 3.31 - 3.39 (m, 2 H) 3.53 - 3.71 (m, 4 H) 3.93 (s, 3 H) 4.34 (br. s., 1 H) 4.44 (s, 2 H) 6.67 (d, J=3.51 Hz, 1 H) 7.17 (d, J=7.40 Hz, 1 H) 7.24 - 7.31 (m, 3 H) 7.52 (d, J=3.51 Hz, 1 H) 7.63 (d, J=5.27 Hz, 1 H) 7.72 (s, 1 H) 7.93 (d, J=5.52 Hz, 1 H) 8.40 (br. s., 2 H) 9.01 (s, 1 H). LCMS (m/z): 415.2 [M+H]+
  • 4
  • [ 64-18-6 ]
  • [ 1060816-67-2 ]
  • [ 1616099-47-8 ]
  • 1-(3,4-dihydroisoquinolin-2(1H)-yl)-3-(3-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)phenoxy)propan-2-ol formate [ No CAS ]
YieldReaction ConditionsOperation in experiment
11.4% To a solution of <strong>[1060816-67-2]2-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine</strong> (70 mg, 0.407 mmol) in dioxane (4 ml) and H20 (1 mL) was added compound l-(3,4-dihydroisoquinolin- 2(lH)-yl)-3-(3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy)propan-2-ol (200 mg, 0.4886 mmol), Pd(dppf)Cl2 (30 mg, 0.041 mmol) and K2C03 (169 mg, 1.221 mmol) at 15C. The reaction mixture was then stirred for 16 h at 100C after which, TLC analysis showed the reaction to be complete. The reaction mixture was the filtered and the filtrate concentrated to remove the solvent with the residue purified by prep-HPLC to give the formate salt of the title compound (23 mg, 11.4%) as a white solid. 1H NMR (400 MHz, CDC13): delta 8.99 (s, IH), 8.10-8.08 (m, 2 H), 7.47-7.42 (m, 2H), 7.39-7.24 (m, 3H), 7.20 (d, J=6.8 Etazeta,IotaEta), 7.10 (dd, J=2.0, 8.0 Hz, IH), 6.66 (d, J=3.6 Etazeta,IotaEta), 4.55-4.52 (m, IH), 4.42 (s, 2H), 4.20-4.17 (m, 2H), 3.94(s, 3H), 3.57-3.54 (m, 2H), 3.45-3.25 (m, 2H), 3.19 (d, J=3.6 Hz, 2H) ppm. LCMS (m/z): 326.1 [M+H]+.
  • 5
  • [ 1060816-67-2 ]
  • 5,5-dibromo-2-chloro-7-methyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one [ No CAS ]
YieldReaction ConditionsOperation in experiment
With N-Bromosuccinimide; In water; tert-butyl alcohol; at 20℃; for 3h; Step-2: 5,5-Dibromo-2-chloro-7-methyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one [0183] To a solution of <strong>[1060816-67-2]2-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine</strong> (835 mg, 5 mmol) in t-BuOH/H2O ((10 mL/3 mL) was added NBS (2.67 g, 15 mmol) and stirred for 3 h at room temperature. The reaction mixture was concentrated and dissolved in EtOAc (30 mL). The EtOAc layer was washed with NaHCO3, brine, dried (Na2SO4) and concentrated to give crude 5,5-Dibromo-2-chloro-7-methyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one (1.72 g) which was used for the next step.
  • 6
  • [ 1060816-67-2 ]
  • 2-chloro-7-methyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one [ No CAS ]
  • 7
  • [ 1060816-67-2 ]
  • (S)-6-chloro-3-(1-((7-methyl-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)ethyl)quinolin-2(1H)-one [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 1060816-67-2 ]

Chlorides

Chemical Structure| 90213-67-5

A116651 [90213-67-5]

2,4-Dichloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine

Similarity: 0.87

Chemical Structure| 90213-66-4

A181078 [90213-66-4]

2,4-Dichloro-7H-pyrrolo[2,3-d]pyrimidine

Similarity: 0.83

Chemical Structure| 7781-10-4

A372795 [7781-10-4]

4-Chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine

Similarity: 0.81

Chemical Structure| 1192711-71-9

A208020 [1192711-71-9]

2,4-Dichloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine

Similarity: 0.78

Chemical Structure| 1367986-07-9

A232516 [1367986-07-9]

2-Chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine

Similarity: 0.78

Related Parent Nucleus of
[ 1060816-67-2 ]

Other Aromatic Heterocycles

Chemical Structure| 90213-67-5

A116651 [90213-67-5]

2,4-Dichloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine

Similarity: 0.87

Chemical Structure| 90213-66-4

A181078 [90213-66-4]

2,4-Dichloro-7H-pyrrolo[2,3-d]pyrimidine

Similarity: 0.83

Chemical Structure| 7781-10-4

A372795 [7781-10-4]

4-Chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine

Similarity: 0.81

Chemical Structure| 1638760-44-7

A294173 [1638760-44-7]

5-Methyl-7H-pyrrolo[2,3-d]pyrimidine

Similarity: 0.79

Chemical Structure| 1192711-71-9

A208020 [1192711-71-9]

2,4-Dichloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine

Similarity: 0.78